Laboratoires Pierre Fabre and XtalPi Announce Innovative Collaboration Leveraging AI for Drug Discovery
In a significant development for the pharmaceutical industry, Laboratoires Pierre Fabre and XtalPi have revealed a groundbreaking partnership aimed at enhancing drug discovery through artificial intelligence (AI). This collaboration opens new avenues for developing clinical candidates for various therapeutic areas, primarily oncology, and potentially dermatology and rare diseases.
Under this collaboration, XtalPi will leverage its advanced AI capabilities and robotic platform to design novel therapies based on small molecules that target previously unexplored biological pathways. In turn, Laboratoires Pierre Fabre will contribute its extensive expertise in disease biology, drug discovery, translational research, and clinical development. This ensures that the most promising compounds are selected and progressed efficiently, with Laboratoires Pierre Fabre responsible for the subsequent clinical and commercial development.
This alliance signifies a shared commitment to tackle complex therapeutic targets that have historically been difficult to address, particularly in areas with significant unmet medical needs and opportunities for innovative drug discoveries. By combining XtalPi's state-of-the-art AI and robotics with Laboratoires Pierre Fabre's deep experience in therapeutic development, both companies aim to accelerate the identification of high-quality clinical candidates.
Raymond Zheng, Director of Integrated Drug Discovery at XtalPi, expressed his enthusiasm about the collaboration, stating, "We are honored to establish this collaboration with Laboratoires Pierre Fabre, a respected international pharmaceutical company. This alliance merges XtalPi’s strengths in AI and robotics with Laboratoires Pierre Fabre’s prowess in therapeutic development, aiming to advance promising preclinical candidates for the benefit of patients with unmet medical needs."
Francesco Hofmann, Director of Pharmaceutical Research and Development at Laboratoires Pierre Fabre, noted, "Partnering with XtalPi represents a significant milestone for us. Utilizing XtalPi's AI expertise to accelerate the acquisition of high-quality clinical candidates across multiple targets is a vital addition to our R&D data and intelligence roadmap, as well as our discovery engine."
The agreement entails an initial payment, various milestone payments, and a share in future economic benefits; however, specific financial terms were not disclosed. This collaboration reflects the growing trend of incorporating AI technologies in drug discovery, promising to enhance efficiency and the scope of therapeutic options in the pharmaceutical landscape.
With both companies dedicated to addressing pressing medical challenges, the outcomes of this collaboration could play a pivotal role in the development of new, effective treatments for patients who need them the most. As the field of drug discovery continues to evolve with the integration of advanced technologies, this partnership stands as a testament to the innovative spirit that drives progress in healthcare. For more updates on this and other initiatives, please visit Laboratoires Pierre Fabre and follow them on social media platforms to stay informed on the latest advancements in drug discovery and development.
Under this collaboration, XtalPi will leverage its advanced AI capabilities and robotic platform to design novel therapies based on small molecules that target previously unexplored biological pathways. In turn, Laboratoires Pierre Fabre will contribute its extensive expertise in disease biology, drug discovery, translational research, and clinical development. This ensures that the most promising compounds are selected and progressed efficiently, with Laboratoires Pierre Fabre responsible for the subsequent clinical and commercial development.
This alliance signifies a shared commitment to tackle complex therapeutic targets that have historically been difficult to address, particularly in areas with significant unmet medical needs and opportunities for innovative drug discoveries. By combining XtalPi's state-of-the-art AI and robotics with Laboratoires Pierre Fabre's deep experience in therapeutic development, both companies aim to accelerate the identification of high-quality clinical candidates.
Raymond Zheng, Director of Integrated Drug Discovery at XtalPi, expressed his enthusiasm about the collaboration, stating, "We are honored to establish this collaboration with Laboratoires Pierre Fabre, a respected international pharmaceutical company. This alliance merges XtalPi’s strengths in AI and robotics with Laboratoires Pierre Fabre’s prowess in therapeutic development, aiming to advance promising preclinical candidates for the benefit of patients with unmet medical needs."
Francesco Hofmann, Director of Pharmaceutical Research and Development at Laboratoires Pierre Fabre, noted, "Partnering with XtalPi represents a significant milestone for us. Utilizing XtalPi's AI expertise to accelerate the acquisition of high-quality clinical candidates across multiple targets is a vital addition to our R&D data and intelligence roadmap, as well as our discovery engine."
The agreement entails an initial payment, various milestone payments, and a share in future economic benefits; however, specific financial terms were not disclosed. This collaboration reflects the growing trend of incorporating AI technologies in drug discovery, promising to enhance efficiency and the scope of therapeutic options in the pharmaceutical landscape.
With both companies dedicated to addressing pressing medical challenges, the outcomes of this collaboration could play a pivotal role in the development of new, effective treatments for patients who need them the most. As the field of drug discovery continues to evolve with the integration of advanced technologies, this partnership stands as a testament to the innovative spirit that drives progress in healthcare. For more updates on this and other initiatives, please visit Laboratoires Pierre Fabre and follow them on social media platforms to stay informed on the latest advancements in drug discovery and development.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.